Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1922 1
1941 1
1945 1
1946 2
1947 1
1948 2
1950 3
1951 6
1952 4
1954 2
1956 1
1957 3
1958 2
1959 2
1960 2
1961 2
1962 4
1963 7
1964 4
1965 1
1966 1
1967 2
1970 5
1971 5
1972 2
1973 3
1974 2
1975 2
1976 4
1977 6
1978 7
1979 7
1980 10
1981 11
1982 10
1983 9
1984 18
1985 13
1986 21
1987 11
1988 21
1989 12
1990 24
1991 21
1992 23
1993 31
1994 32
1995 40
1996 25
1997 29
1998 15
1999 25
2000 30
2001 28
2002 20
2003 39
2004 50
2005 40
2006 38
2007 33
2008 43
2009 46
2010 49
2011 37
2012 46
2013 69
2014 70
2015 71
2016 87
2017 108
2018 92
2019 101
2020 154
2021 217
2022 242
2023 207
2024 241
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,406 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Agarwal R, et al. Among authors: joseph a. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777. Eur Heart J. 2022. PMID: 35023547 Free PMC article. Clinical Trial.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. Among authors: joseph a. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. Among authors: joseph a. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Jaundice.
Joseph A, Samant H. Joseph A, et al. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31334972 Free Books & Documents.
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Małyszko J, Ruilope LM, Rossignol P, Rossing P, Pecoits-Filho R, Anker SD, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL. Agarwal R, et al. Among authors: joseph a. Clin Kidney J. 2022 Oct 30;16(2):293-302. doi: 10.1093/ckj/sfac234. eCollection 2023 Feb. Clin Kidney J. 2022. PMID: 36864892 Free PMC article.
Hemodynamic effects of positive end-expiratory pressure.
Joseph A, Petit M, Vieillard-Baron A. Joseph A, et al. Curr Opin Crit Care. 2024 Feb 1;30(1):10-19. doi: 10.1097/MCC.0000000000001124. Epub 2023 Nov 29. Curr Opin Crit Care. 2024. PMID: 38085886 Review.
Severe Community-Acquired Pneumonia in Immunocompromised Patients.
Chean D, Windsor C, Lafarge A, Dupont T, Nakaa S, Whiting L, Joseph A, Lemiale V, Azoulay E. Chean D, et al. Among authors: joseph a. Semin Respir Crit Care Med. 2024 Apr;45(2):255-265. doi: 10.1055/s-0043-1778137. Epub 2024 Jan 24. Semin Respir Crit Care Med. 2024. PMID: 38266998 Review.
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL; FIDELIO-DKD Investigators. Agarwal R, et al. Among authors: joseph a. J Am Soc Nephrol. 2022 Jan;33(1):225-237. doi: 10.1681/ASN.2021070942. Epub 2021 Nov 3. J Am Soc Nephrol. 2022. PMID: 34732509 Free PMC article. Clinical Trial.
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Sarafidis P, et al. Among authors: joseph a. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7. Clin J Am Soc Nephrol. 2023. PMID: 36927680 Free PMC article. Clinical Trial.
2,406 results